ArticleImmunologic research2026
Association of isolated anti-Scl-70 positivity with subclinical cardiac involvement in ANA-positive individuals: an electrocardiographic diastolic function analysis (Subclinical Cardiac Involvement in Isolated Anti-Scl-70 Positivity).
Article in Immunologic research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-topoisomerase I (anti-Scl-70) antibodies are strongly associated with systemic sclerosis and fibrotic organ involvement. However, their significance in ANA-positive individuals without established systemic sclerosis remains unclear. We investigated whether isolated anti-Scl-70 positivity is associated with subclinical cardiac involvement. This retrospective single-center study included 486 ANA-positive individuals identified between 2016 and 2026. Patients were classified as anti-Scl-70-positive (n = 242) or anti-Scl-70-negative (n = 244). Individuals with systemic sclerosis, other rheumatologic diseases, cardiovascular disease (except hypertension), malignancy, or advanced renal/hepatic disease were excluded. All anti-Scl-70-positive patients remained free of systemic sclerosis during at least 12 months of follow-up. Electrocardiographic Diastolic Index-1 (EDI-1) and EDI-2 were calculated from standard 12-lead ECGs. Demographic characteristics, inflammatory markers, ANA titers, and most ENA antibodies were similar between groups. Anti-Ro52 positivity was more frequent in anti-Scl-70-positive individuals (p = 0.004). EDI-1 was significantly lower, whereas EDI-2 was significantly higher in the anti-Scl-70-positive group (both p < 0.001). Among patients with available echocardiographic data, anti-Scl-70-positive individuals demonstrated higher E/e' ratios (p = 0.004) and lower LV-GLS values (p = 0.046). EDI-1 showed a strong correlation with E/e' (r
Indexed as
Identifiers
42572046What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.